Not medical advice. PEG-MGF is a research compound. This guide does not provide dosing, diagnosis, therapy recommendations, or claims about effects in humans.
PEG-MGF is the PEGylated long-acting form of Mechano Growth Factor, engineered to turn a local 5-minute signal into a systemically active peptide that can reach satellite cells across multiple muscle groups from a single injection.
One-paragraph overview from our research datasheet — still scientific, but faster to read than the full mechanism list below.
PEG-MGF PEGylated Mechano Growth Factor extends native MGF half-life from minutes to hours via polyethylene glycol conjugation for systemic satellite cell activation.
Peer-reviewed literature typically discusses PEG-MGF in specific experimental settings. The points below reflect how the scientific community frames this compound—not as health claims, but as the research questions being asked.
Research vs. personal use: Literature describes experiments in controlled lab and animal models. This is distinct from any real-world use; our products are for laboratory research only.
Here the literature centres on muscle repair, growth-factor signalling, and how tissues respond after overload or injury in preclinical work.
Our datasheet lists mechanistic themes observed in preclinical work. These are research endpoints, not health claims. They help scientists understand and compare pathways.
Storage requirements: Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. Use within the validated stability window for the specific batch and formulation. · Learn best practices in our detailed storage guide.
Research dosing context: Literature typically discusses 200-500 μg subcutaneously · 2-3 times weekly; site-specific injection not required due to extended half-life · Extended t½ estimated at several hours to days (vs 5-7 min for native MGF). Core peptide MW ~2848 Da; total MW varies with PEG chain size. Single SC injection provides systemic distribution, distinct from native MGF which requires site-specific IM administration. Metabolized in liver and kidneys via standard peptide degradation. Not FDA-approved; limited human clinical data.
Preparation steps: Follow our detailed reconstitution guide, use the calculator tool for volume confirmation, and always verify purity with the COA reading guide.
PEG-MGF is the PEGylated, long-acting form of Mechano Growth Factor - the 24-amino-acid IGF-1Ec E-domain peptide with a polyethylene-glycol chain attached. The PEG shield converts a local, minutes-long satellite-cell signal into a systemically active peptide that can reach muscle groups across the body from a single subcutaneous injection. It is supplied here for laboratory research only and is not for human use.
They share the same E-domain and the same non-IGF-1R satellite-cell-activating mechanism. The difference is pharmacokinetics: native MGF is cleared in 5-7 minutes and must be injected site-specifically into the target muscle, while PEG-MGF's PEG shield extends the half-life to hours or days, enabling systemic action from one injection. PEG-MGF is the form used in research that needs whole-body or multi-muscle reach.
PEGylation extends the half-life well beyond native MGF's 5-7 minutes - vendor and educational sources commonly cite a window of many hours up to roughly 48-72 hours depending on PEG chain size. These figures are estimates rather than peer-reviewed human pharmacokinetics; no published human PK study of PEG-MGF exists. The point of the modification is the qualitative shift from a local to a systemic signal.
Because the 5-7 minute half-life of native MGF means that injected peptide is degraded or cleared long before it can reach distal muscle groups. No amount of dose escalation fixes that - you would just have higher peak concentrations for the same brief window. PEGylation fundamentally changes the pharmacokinetics rather than just the dose.
Yes - the two peptides operate through different pathways (non-IGF-1R satellite cell activation for MGF; full IGF-1R signalling for IGF-1 LR3) and are sometimes used together in research protocols to target both the stem cell recruitment and terminal differentiation arms of muscle growth.
PEG-MGF is sold strictly as a research-use-only laboratory compound and is not an approved drug for human use. For competing athletes it is prohibited at all times under WADA category S2 (peptide hormones, growth factors, related substances and mimetics). New-U supplies it for in-vitro and preclinical research only.
Keep the lyophilised powder frozen at −20 °C. After reconstitution with bacteriostatic water, refrigerate at 1-6 °C and protect from light. The PEG chain improves stability compared with native MGF, but the underlying peptide is still subject to normal handling precautions.
No, and no. This article is educational only. We do not provide dosing, medical recommendations, or health claims. Our products are sold strictly for laboratory research, not for personal use of any kind.
Open the shop listing via “View product details.” There you will see batch specs, the Certificate of Analysis (COA), concentration, purity grade, and available SKUs with current pricing.
Primary literature and registries for PEG-MGF, plus mainstream coverage of the peptide category. Research use only - not medical advice.
Databases & literature:
Peptides in the news:
Access concentration, batch info, variants, and current pricing on our shop.
Also known as: PEG-MGF, PEGylated Mechano Growth Factor, PEGylated IGF-1Ec, PEGylated MGF, Pegylated Mechano Growth Factor, Long-Acting MGF